Henry Schein Investment Research from a Long-Term Business Owner's Perspective

On dependencies, customer concentration is low, but supply chain importance is high. 【Fact】The company discloses no single major customer. Its top ten distribution suppliers together account for about 25% of purchases, and the largest single supplier accounts for about 4%. However, certain raw materials or products may be available from only one or a small number of suppliers because of quality, regulatory, and availability constraints. In other words, the company is less exposed to the loss of one major customer, but more exposed to supply chain disruption, manufacturer direct sales, and upstream bargaining power.

If the stock market closed for five years, my attitude toward this business would be: 【View】I would be willing to hold it, provided the purchase price were lower. The business itself is understandable, and demand will not disappear out of thin air. But at today's price, buying the whole company would look more like buying a medium-quality, still-improving enterprise at a reasonable price than buying a high-barrier business at a cheap price.

The judgments in the table are based on the company's 10-K, investor relations materials, and industry data.

Industry and Competitive Landscape

【Fact】The company describes its competitive environment very directly: the medical and dental distribution industry is "highly competitive," with competition mainly on price, product breadth, e-commerce capability, customer service, and value-added services. In U.S. dental distribution, the main competitors are Patterson Dental and Benco. In medical distribution, important competitors include McKesson and Medline. In specialty products, competition comes from Straumann, Envista, ZimVie, and Dentsply Sirona. In technology software, competitors include Patterson's Eaglesoft, Carestream, Open Dental, Curve, CareStack, Epic, and others.

【Inference】Therefore, HSIC's industry is not in decline. It is a segment-upgrade track within a mature industry. Core distribution is mature, low-margin, and driven by scale and execution. Software, specialty products, and practice-tech are better sub-industries with higher margins and stronger stickiness, but they are not yet large enough to fully reshape the company's overall profile. The company is worth studying not because distribution itself is attractive, but because it has a chance to convert distribution traffic into higher-quality ancillary revenue. This logic is consistent with management's current strategy: in Q1 2026, the company again emphasized that through BOLD+1 and value creation initiatives, it hopes to achieve more than $200 million in annualized operating income improvement over the next few years and reach a $125 million run-rate by the end of 2026.

Long-term demand is generally stable. 【Fact】CMS's official forecast for U.S. health expenditures in 2024-2033 shows that overall healthcare spending is expected to grow faster than GDP over the long term, with average growth of about 5.8% in 2024-2033, and physician and clinical services are still expected to maintain positive long-term growth. Separately, CDC data show that in 2022, 63.7% of Americans aged 65 and above had seen a dentist in the previous 12 months, meaning aging has not eliminated demand for dental services. Home care also has long-term demand. CMS 2026 materials show that in 2021, the United States had 11,474 Medicare-certified home health agencies, and about 3 million Medicare FFS beneficiaries used home health care.

Still, the industry is not as stable as a utility. 【Fact】The company itself clearly flags that manufacturer direct sales, peer consolidation, third-party online e-commerce platforms, greater price transparency, and regulatory changes may all compress its role and profits. The 2023 cybersecurity incident materially affected dental and medical distribution operations in North America and Europe, and the company continued to disclose costs and insurance recoveries related to the incident in 2024 and 2025. This shows that the industry depends heavily on system availability and execution discipline.

Moat and Management Capital Allocation

Moat Analysis

Henry Schein's moat is not a single type. It is a stack of several medium-strength advantages. 【View】Companies of this kind usually do not have a Coca-Cola-style brand monopoly, nor do they have network effects as strong as Visa's. Their competitive resistance comes more from a combined "hassle cost" created by front- and back-office systems, logistics reach, supplier relationships, customer habits, software embedding, private label, and sales networks.

The assessment is based on company annual reports, IR materials, and proxy disclosures.

【Inference】The company's overall moat is roughly 3/5: The core distribution moat is stable but not wide; the moat in technology and specialty is widening; combined, the company's overall moat is stable to slightly improving, but not strong enough to ignore price competition or channel shock. A competitor trying to replicate the full package of "global dental distribution + field service + software + specialty" would usually need many years and substantial acquisition capital. But replicating a single submodule, such as low-price e-commerce distribution or one software point solution, is not prohibitively difficult.

Performance under inflation and recession also shows that it is not a "strong pricing power company." 【Fact】ADA reports show that dental equipment and consumables price indexes have risen significantly since 2015. Henry Schein's Q1 2026 gross margin rose only 24 basis points year over year to 31.79%, showing that the company can partly pass through costs and improve mix, but the pace of improvement is modest. Meanwhile, even through the 2023 cyber incident, 2024 post-COVID destocking, and dental-cycle volatility, the company remained profitable in 2023-2025 and generated operating cash flow every year. Put differently: recession resistance is acceptable, while strong pricing power is lacking.

Management and Capital Allocation

Management integrity and long-term orientation should be assessed separately. 【Fact】Stanley Bergman completed the CEO transition around March 2, 2026, with Frederick M. Lowery becoming the new CEO. The company's proxy discloses that directors and executives together held only about 0.89% of shares, Bergman himself held about 0.50%, and KKR and its affiliates held about 16.43% as of March 23, 2026. The company requires the CEO to hold shares worth at least 6x annual salary, executives reporting directly to the CEO to hold at least 3x annual salary, and both executives and directors are subject to anti-hedging, anti-pledging, and clawback restrictions.

【View】This means management mechanisms are healthier than those at companies with distorted incentives, but the structure is not the typical Buffett favorite where a founder-major shareholder is highly aligned with minority shareholders. Executive personal ownership is not especially high. The party with greater governance influence is KKR, along with segment adjustment, the CEO transition, and execution of the value creation plan. For conservative investors, this is a neutral to cautious signal, not a major positive.

There are three major capital allocation items: buybacks, M&A, and no dividend. 【Fact】The company has long paid no dividend and explicitly states that it currently does not expect to pay cash or stock dividends in the foreseeable future. By the end of 2025, the company had cumulatively repurchased about $6.0 billion of shares, totaling about 107.9 million shares. By the end of Q1 2026, cumulative repurchases were about $6.1 billion and about 109.5 million shares, with $655 million of authorization remaining. In 2025, the company also executed a $250 million ASR, while issuing 3.285 million shares to KKR in a private placement and raising $250 million.

【Inference】The buybacks themselves are not bad: from 2020 to the end of 2025, shares outstanding fell from about 142.5 million to about 115.8 million, a decline of about 18.7%, making a real contribution to per-share value. The issue is that in 2025, the company was repurchasing aggressively at prices above $70, while also doing a strategic issuance and multiple acquisitions. This looks more like a package of "shareholder structure adjustment + accelerated transformation" than an extremely disciplined Buffett-style operation that repurchases heavily only when shares are clearly undervalued.

M&A has created directional value while also bringing asset-quality concerns. 【Fact】In 2023, the Shield Healthcare transaction consideration was about $348 million, and the S.I.N. Implant System consideration was about $329 million. In 2023-2025, "equity investments and business acquisitions, net of cash acquired" were $955 million, $230 million, and $199 million, respectively. Meanwhile, goodwill rose from $2.893 billion at the end of 2022 to $4.213 billion at the end of 2025.

【View】My conclusion on capital allocation is: the direction is broadly rational, while the results still need proof. Management knows it should migrate the business toward higher-margin, stickier areas, and it has started to put ROIC into long-term incentive metrics. The proxy also discloses that the 2025 LTIP changed to 50% three-year cumulative EPS + 50% three-year average ROIC, and the 2025 and 2026 PSU payouts were not "artificially beautified," with low payout rates of 0% and 21.5%, respectively. This suggests the assessment is not purely ceremonial. The issue is that there have been too many "adjustments" over the past few years: restructuring, amortization, impairments, cybersecurity insurance net items, shareholder advisory, and value creation consulting expenses have appeared repeatedly, reducing the cleanliness of non-GAAP figures.

Financial Quality and Owner Earnings

Financial Quality in Recent Years

The table is drawn from the company's 2021, 2022, 2024, and 2025 annual reports. For 2023-2025, "conservative FCF" additionally deducts capitalized software costs that are separately listed in the cash flow statement. For 2020-2022, the financial statement summaries did not separately list this item, so the FCF figures for the earlier years are slightly optimistic.

Looking at these numbers together leads to several conclusions. 【Fact】First, revenue CAGR in 2020-2025 was about 5.4%, but excluding the PPE/COVID-related lift in 2021, revenue CAGR in 2022-2025 was only about 1.4%. Second, gross margin has improved meaningfully from 2020, but GAAP operating margin in 2023-2025 still hovered around 5%. Third, operating cash flow is generally real and exceeded net income attributable to shareholders in most years, but 2024 operating cash flow of $848 million was materially helped by working capital release and should not be extrapolated mechanically.

Returns on capital are not bad, but they are not excellent either. 【Inference】On a rough shareholder-attributable basis, ROE appears to have fallen from its 2021 high to about 11%-12% in 2023-2025, while ROA fell to about 3.7%-4.3%, and ROIC declined from about 13% in 2022 to about 8%-9% in 2023-2025. These figures show that Henry Schein is not a low-quality company, but it has not consistently shown the kind of high return on capital that immediately signals a hard moat.

The balance sheet also needs to be viewed from both sides. 【Fact】At the end of 2025, the company had cash of $156 million and total debt of about $3.107 billion. At the end of Q1 2026, cash was $138 million and total debt was about $3.408 billion. Roughly estimating on 2025 GAAP EBITDA, debt/EBITDA was around 3x. In 2025, EBIT/interest expense was about 4.35x, and EBITDA/interest expense was about 6.4x. The company is not at a "dangerous" level, but it is clearly not a comfortable net-cash balance sheet either.

Working capital is critical to understanding cash flow. 【Fact】In Q1 2026, operating cash flow turned into a net outflow of $97 million. Management explained that this mainly came from working capital changes in receivables, inventory, and payables. The company also disclosed that business seasonality typically makes Q1 working capital needs higher than year-end levels. In Q1 2026, DSO rose to 45.7 days and inventory turns fell to 4.6. In other words, short-term cash volatility does not necessarily mean business deterioration, but it again reminds us that this is a business highly dependent on working capital management.

On accounting quality, I have not seen obvious evidence of fraud, but I do see complexity that must be monitored continuously. 【View】The positives are: BDO has audited the company for a long time, the company remains profitable, and operating cash flow broadly matches earnings. This does not look like a story where profit looks good while cash never follows. The negatives are: frequent acquisitions, minority interests and redeemable interests, high goodwill and intangible asset weight, and many non-GAAP adjustments over the years. This combination does not mean there is a problem, but it absolutely means investors cannot be lazy.

Owner Earnings Analysis

I prefer to estimate Henry Schein's "owner earnings" using a conservative approach. 【Fact】In 2025, net income attributable to shareholders was $398 million; depreciation and amortization was $311 million; operating cash flow was $712 million; PP&E capital expenditure was $139 million, and capitalized software was $52 million.

【Inference】From an owner's perspective: I prefer to start from operating cash flow, because it has already deducted interest and taxes and reflects the year's actual working capital use. Then, I would not treat stock-based compensation as an ignorable non-cash item; nor would I treat the full $191 million of total investment as pure growth capex. A more conservative approach is to assume 2025 maintenance capex of about $160 million to $180 million. On that basis, 2025 owner earnings would be roughly $530 million to $550 million. Applying an additional conservative haircut to cover recurring restructuring/integration/IT investments and cyclical working capital disturbance, a more prudent Owner Earnings baseline would be about $500 million. This figure is higher than 2025 net income attributable to shareholders, showing that the company's profit is broadly "real money," not paper profit.

Based on the current market capitalization of about $8.89 billion, the current price roughly implies: P/Owner Earnings ≈ 17.8x; based on 2025 conservative FCF of $521 million, P/FCF ≈ 17.1x, and the free cash flow yield is about 5.9%. This is higher than the roughly 4.45% U.S. 10-year Treasury yield at the end of May 2026, but only by about 1.4 percentage points. The risk premium is not especially thick.

Intrinsic Value and Margin of Safety

Current Valuation and Cross-Check Through Three Methods

First, look at the current valuation cross-section. 【Inference】Based on the latest share price and recent annual/quarterly data, HSIC is roughly in these ranges: trailing PE about 23.1x; P/B about 2.7x; EV/EBITDA based on 2025 GAAP EBITDA about 12.6x; and P/FCF based on 2025 conservative FCF about 17.1x. The company's 2026 guidance is for sales growth of 3%-5% and non-GAAP diluted EPS of $5.23-$5.37, which means the current share price corresponds to forward non-GAAP PE of about 14.3-14.6x. But this must be emphasized: over the past few years, the non-GAAP basis has often excluded restructuring, amortization, impairments, cybersecurity insurance net items, and some advisory/value creation costs, so this forward PE cannot be treated as sufficient evidence of natural cheapness.

Method One: Owner Earnings Discounting. I use an equity cash flow approach, so I do not deduct net debt again. Using 2025 conservative Owner Earnings as the starting point, I model three scenarios:

【View】For a conservative value investor, the side that deserves real reliance is the "base-to-conservative" side, not the optimistic case. From that perspective, the current share price of $76.58 is roughly near the lower end of the base value range, but still some distance from "clearly cheap." The core valuation fragility is not revenue, but whether margin improvement is delivered. If operating margin cannot rise sustainably, return elasticity at the current price will become ordinary. The valuation inputs come from the 2025 annual report, the Q1 2026 report, and the latest share price.

Method Two: Relative Valuation. 【Fact】As of the end of May 2026, McKesson's trailing PE was about 21.4x, Cencora's was about 20.6x, and Henry Schein's was about 23.1x.

【View】This comparison is imperfect because MCK/COR are more drug-distribution-oriented and differ in scale and moat, but it at least says one thing: HSIC is not receiving an obvious discount for weaker business quality. If a company with operating margin of only about 5%, highly competitive core distribution, and higher acquisition and intangible asset exposure trades at a similar or even higher trailing PE than stronger, larger industry platforms, its sense of cheapness must be discounted. Conversely, using 2026 non-GAAP guidance, HSIC's forward PE has indeed fallen into a mid-to-low range, so the stock is not significantly overvalued. It is simply "not easy money."

Method Three: Asset/Liquidation Value. 【Fact】At the end of 2025, the company had goodwill of $4.213 billion and other intangible assets of $1.018 billion, while equity attributable to shareholders was only $3.245 billion. In other words, tangible net assets were negative.

【View】This almost directly negates an investment logic based on book-asset support. Henry Schein should be valued on earnings power, not liquidation value. If the operating logic deteriorates, the balance sheet will not provide much cushion. For conservative investors, this is a reason to demand a higher margin of safety.

Final Value Range and Margin of Safety

Combining the three methods, I would give the following ranges:

At the current price of $76.58: relative to the conservative range, there is no margin of safety; relative to the reasonable range, there is only a very limited discount; relative to the optimistic range, there is upside, but it depends on execution instead of pure cheapness.

Therefore, my price bands are: Ideal buy price: $58-$65; Acceptable holding price: $65-$85; Clearly overvalued range: above $95.

【View】At present, this is not a "bad company at a good price." It is closer to a "decent company at a fair price." For a balanced but conservative 10-year holder, a name like this usually belongs on a watchlist rather than in an urgent large position.

Risks and Opposing View

The most important risk is not short-term share price volatility. It is mistaking it for a high-quality company when it is only a medium-quality company.

The risk assessment is based on company risk disclosures, competitive disclosures, cyber incident disclosures, and financial data.

The strongest opposing view is actually quite forceful: 【Opposing View】"Henry Schein is essentially still a highly competitive, low-to-mid-margin distributor. Software and specialty are positives, but they are not yet enough to lift overall business quality significantly. Margins have not risen meaningfully over the past few years, while heavy M&A has pushed goodwill higher. What you are buying today is not a high-quality company wrongly punished by the market, but an ordinary good company whose long-term returns may only hover in the mid-to-high single digits." This bearish logic is not absurd.

What facts would overturn my neutral-to-cautious view? If the following facts appear over the next two to three years, I would admit the judgment was wrong and reassess: First, BOLD+1 and the value creation plan truly lift GAAP operating margin steadily to 6%+, and this is not achieved through endlessly adjusting items; second, technology and specialty keep contributing more profit, proving that the company's overall moat is materially widening; third, net debt/EBITDA declines steadily, instead of buying growth through more M&A. Conversely, if these facts do not appear, or if they develop in the opposite direction, the stock could easily become an opportunity-cost asset that "does not lose much, but also does not earn much over ten years," even if it does not collapse.

The largest permanent capital loss scenario is: 【View】Competition in core distribution intensifies, direct sales/online penetration rises, software and specialty improvements fall short of expectations, acquired assets are impaired, and the market reprices HSIC from "fairly valued" to "ordinary distributor." In that scenario, if earnings per share fall to around $3 and the market gives only about 12x earnings, a share price decline to $35-$40 is not unimaginable, corresponding to possible permanent loss of nearly 40%-50%.

Comparisons, Checklist, and Final Judgment

Comparison with Other Opportunities

Compared with the strongest industry competitors, I do not think HSIC has a clear advantage. 【View】If I could only choose a stronger platform in this broad track, in public markets I would be more inclined to view McKesson or Cencora as stronger, larger, and more operationally resilient assets. In the more direct comparable area of dental distribution, Patterson was privatized in 2025, which shows that public comparables are not ideal and also that this track is not a comfortable industry full of high-quality pure public comparables.

Compared with indexes, HSIC also has not offered sufficiently strong historical evidence. 【Fact】The company disclosed in its 2025 annual report that if $100 had been invested at the end of 2020 into HSIC, the Dow Jones U.S. Health Care Index, and the Nasdaq Composite, respectively, the amounts would have become about $115.57, $144.40, and $191.20 by the end of 2025.

Compared with the risk-free rate, the current risk premium is not particularly thick. 【Inference】Based on 2025 conservative FCF, HSIC's FCF yield is about 5.9%, only around 1.4 percentage points higher than the roughly 4.45% U.S. 10-year Treasury yield at the time. For a low-margin, highly competitive business with a high intangible asset ratio and management transition underway, that compensation is not especially generous.

The conclusion is straightforward: 【View】Buying it is not clearly superior to buying an index. Its expected return is likely enough to beat long-term bonds, but may not beat broad equity indexes by a meaningful margin. If my portfolio could hold only 5 assets, Henry Schein would not firmly earn a seat today. If the portfolio had 15-20 assets and I were looking for a "medium-quality, reasonable-price" holding, it could enter the candidate pool.

Investment Checklist

Final Investment Conclusion

【Final Rating】 Watch

【One-Sentence Investment Thesis】 Henry Schein is a real, necessary medical/dental platform company with credible cash flow, but its core distribution moat is not wide enough, and the current price does not yet provide enough margin of safety for a conservative long-term investor.

【Core Bull Case】 First, demand exists over the long run, the customer base is broad, and consumables plus software revenue have recurring characteristics. Second, the company is migrating its profit structure toward higher-margin specialty and technology, and that direction is right. Third, operating cash flow is generally real, and 2025 conservative FCF was still about $521 million. In addition, buybacks have effectively reduced the share count over the long term, with shares outstanding falling by nearly one-fifth from 2020 to the end of 2025. Finally, the company continues to guide for sales growth and profit improvement in 2026, and near-term operations have not stalled.

【Core Bear Case】 First, core distribution is highly competitive, and customer multi-sourcing, manufacturer direct sales, and online platforms limit pricing power. Second, overall GAAP operating margin has still been only about 5% in recent years, showing that the higher-quality transition has not yet fully appeared at the companywide level. Third, goodwill and intangible assets are far higher than tangible net assets, leaving weak liquidation protection. In addition, non-GAAP adjustments have been numerous over the past few years, making it easy for investors to overestimate true earnings quality. Finally, the current valuation is closer to fair than cheap.

【Key Assumptions】 Revenue can maintain low-to-mid-single-digit growth over the next three to five years; technology and specialty businesses continue to increase their profit contribution; GAAP operating margin can at least hold steady and improve gradually; governance changes led by the new CEO and KKR do not damage existing customer relationships or cultural execution; acquisitions do not produce major impairments.

【Fair Buy Price】 $58-$65. The basis is that this range leaves a more meaningful margin of safety for a conservative DCF, the reality of negative tangible net assets, and weaker pricing power in core distribution. At the current price of about $76.58, I do not think it is cheap enough.

【Target Holding Period】 At least 5-10 years. This is not a stock whose value is realized through quarterly trading. Long-term holding only makes sense if software/technology and specialty mix, margins, and per-share cash flow actually materialize.

【Expected Annualized Return】 Based on the Owner Earnings scenario model above, the current price roughly corresponds to: Conservative scenario 6%-8%; Base scenario 9%-10%; Optimistic scenario 11%-13%. These are estimates, not promises. The most sensitive assumptions are margin improvement and the long-term discount rate.

【Maximum Loss Risk】 I think a more realistic worst case is a 40%-50% permanent capital loss. The reason is not that the company goes to zero, but that margins fail to rise, acquisitions are impaired, and the market reclassifies it as an ordinary distributor, causing valuation and earnings to fall at the same time.

【Tracking Indicators】 In the future, I would focus on: organic growth in revenue; the gap between GAAP and non-GAAP operating margins; the profit contribution from technology and specialty; operating cash flow and working capital use; capitalized software and total investment intensity; net debt/EBITDA and interest coverage; share count changes and buyback prices; changes in goodwill/intangible assets; DSO and inventory turns; the delivery pace of the value creation plan's $125 million / $200 million operating income improvement.

【Signals That Would Trigger Reassessment】 If technology growth slows materially; if specialty growth fails to translate into higher returns; if GAAP operating margin remains stuck around 5% for two or three consecutive years; if a major goodwill impairment or another major cyber event occurs; if debt continues to rise while cash flow improvement falls short; I would reassess the entire investment logic.

【Final Recommendation】 Calmly put, Henry Schein is worth studying, but not worth rushing into. It is a business you can understand and that probably will not disappear suddenly. But it is not good enough to ignore price, and it is not cheap enough to ignore quality. For a long-term, conservative investor thinking like a business owner, the most suitable action is not to chase, but to keep tracking, wait for a better price, or wait for the company to first produce stronger evidence on margins and moat.

Open Questions and Limitations: This analysis has three main limitations. First, historical capitalized software data for 2020-2022 were not consistently listed separately in the cash flow summaries I referenced, so the early FCF basis is slightly optimistic. Second, public comparables are imperfect, especially after Patterson was privatized, leaving fewer pure dental distribution comparables. Third, the real driver of valuation elasticity is not revenue, but whether management can convert the "value creation plan" into sustained GAAP margin improvement over the next two to three years.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.